Skip to content

Safety evaluation for excessive intake of supplement containing plant derived extractive

Safety evaluation for excessive intake of supplement containing plant derived extractive - Safety evaluation for excessive intake of supplement containing plant derived extractive

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027769
Enrollment
10
Registered
2017-06-15
Start date
2017-06-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

Intake of supplement containing plant derived extractive, 5-fold quantity of recommended daily intake, for 4 consecutive weeks

Sponsors

TTC Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy males and females aged 20-64 years old

Exclusion criteria

Exclusion criteria: 1.Subjects who constantly use health food richly containing involvement ingredient 2.Subjects who has serious illness such as diabetes, liver disease, kidney disease, heart disease 3.Subjects with allergies to plants, foods and house dust 4.Subjects with allergies to the study 5.Subjects with chronic illness or medication 6.Subjects with an irregular diet habit 7.Subjects who have participated in other clinical study within the last one month or have plan to participate other clinical studies 8.Subjects who are judged as unsuitable for the study from clinical measurements for preliminary tests and measurements 9.Subjects who intend to become pregnant or lactating 10.Male subjects who hope a baby 11.Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire 12.Subjects who are judged as ineligible by clinical investigator

Design outcomes

Primary

MeasureTime frame
Physical, Hematologic, Blood biochemical, Urinalysis, Doctor' s questions, Weight before and 2, 4 weeks after intake and 2 weeks after the end of intake period and Adverse events thorough the study.

Countries

Japan

Contacts

Public ContactKotoha Isobe

TTC Co., Ltd. Clinical Research Planning Department

k.isobe@ttc-tokyo.co.jp03-5459-5329

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026